Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by CEL-SCI Corporation

< Previous 1 2 Next >
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Issues Letter to Shareholders
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI’s Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces Proposed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine’s Approval for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine’s Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI’s Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
From CEL-SCI Corporation
Via Business Wire
Tickers CVM
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.